Stockscreener 앱 받기
1.68
1.18%
-0.02
시간 외 거래:
1.71
0.03
+1.79%
전일 마감가:
$1.70
열려 있는:
$1.72
하루 거래량:
840.66K
Relative Volume:
0.96
시가총액:
$181.91M
수익:
$27.08M
순이익/손실:
$-37.00M
주가수익비율:
-3.2308
EPS:
-0.52
순현금흐름:
$-18.46M
1주 성능:
+2.44%
1개월 성능:
+14.29%
6개월 성능:
-29.71%
1년 성능:
+20.86%
1일 변동 폭
$1.64
$1.76
1주일 범위
$1.62
$1.78
52주 변동 폭
$1.05
$5.17
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
명칭
Aclaris Therapeutics Inc
전화
484-324-7933
주소
701 LEE ROAD, WAYNE, PA
ACRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
1.68 | 184.08M | 27.08M | -37.00M | -18.46M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 재개 | Piper Sandler | Overweight |
| 2025-05-28 | 개시 | Wedbush | Outperform |
| 2025-03-18 | 재개 | Cantor Fitzgerald | Overweight |
| 2024-12-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2024-11-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-19 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | 개시 | Evercore ISI | Outperform |
| 2022-12-14 | 개시 | Stifel | Buy |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2022-10-06 | 개시 | BTIG Research | Buy |
| 2021-07-23 | 재개 | Jefferies | Buy |
| 2021-06-15 | 개시 | Piper Sandler | Overweight |
| 2021-04-21 | 개시 | H.C. Wainwright | Buy |
| 2019-10-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | 개시 | SVB Leerink | Outperform |
| 2018-03-28 | 재개 | Leerink Partners | Outperform |
| 2018-02-09 | 개시 | Guggenheim | Buy |
| 2017-06-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-29 | 개시 | Leerink Partners | Outperform |
| 2016-09-30 | 개시 | JMP Securities | Mkt Outperform |
| 2016-06-10 | 개시 | Guggenheim | Buy |
| 2015-11-02 | 개시 | Citigroup | Buy |
| 2015-11-02 | 개시 | Jefferies | Buy |
모두보기
Aclaris Therapeutics Inc 주식(ACRS)의 최신 뉴스
Biopharma firm with big St. Louis operations names new chief scientific officer - The Business Journals
Aclaris Therapeutics Announces Leadership Transition - GlobeNewswire
Aclaris Appoints Drug Development Veteran Behind 6 FDA-Approved Antibodies as New CSO - Stock Titan
Momentum divergence signals in Aclaris Therapeutics Inc. chartTrend Following Ideas with Volume Confirmation - Newser
Market reaction to Aclaris Therapeutics Inc.’s recent newsFree Expert Verified Stock Trade Ideas - Newser
Using R and stats models for Aclaris Therapeutics Inc. forecasting Free Smart Trend Trading with Weekly Signals - Newser
What is the risk reward ratio of investing in Aclaris Therapeutics Inc. stockHigh-performance stocks for savvy investors - jammulinksnews.com
What are Aclaris Therapeutics Inc. company’s key revenue driversMaximize returns with effective portfolio management - jammulinksnews.com
What are analysts’ price targets for Aclaris Therapeutics Inc. in the next 12 monthsHarness the power of proven investment plans - jammulinksnews.com
What are the latest earnings results for Aclaris Therapeutics Inc.Capitalize on emerging growth stocks - jammulinksnews.com
Published on: 2025-07-28 01:01:49 - jammulinksnews.com
How Resilient Is Aclaris Therapeutics Inc. Stock During Economic DownturnsLong Term Secure Gain Stocks - Newser
Published on: 2025-07-27 19:20:18 - jammulinksnews.com
How Efficient Is Aclaris Therapeutics Inc. at Controlling Operating CostsInsider Level Guidance - Newser
What drives Aclaris Therapeutics Inc. stock priceRapidly expanding wealth - PrintWeekIndia
Aclaris Therapeutics Inc. Stock Analysis and ForecastConsistently high returns - PrintWeekIndia
What institutions are buying Aclaris Therapeutics Inc. stock nowPhenomenal returns - jammulinksnews.com
What analysts say about Aclaris Therapeutics Inc. stockFree Predictions - PrintWeekIndia
Why Aclaris Therapeutics Inc. stock attracts strong analyst attentionFree Professional Portfolio Management - Newser
LENZ Therapeutics Inc. Stock Analysis and ForecastPhenomenal capital appreciation - Autocar Professional
Is Aclaris Therapeutics Inc. a good long term investmentRapid capital growth - jammulinksnews.com
How Aclaris Therapeutics Inc. stock performs during market volatilityDaily Volume Leaders - Newser
What makes Aclaris Therapeutics Inc. stock price move sharplyEntry Level Low Risk Picks - Newser
Aclaris Therapeutics Begins Phase 1 Clinical Trial for Bispecific Antibody ATI-052 Targeting Inflammatory Diseases - Insider Monkey
13 Best Low Priced Pharma Stocks to Buy Now - Insider Monkey
Piper Sandler Begins Coverage on Aclaris Therapeutics (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics' Recent Gains Improve Losses On Insider Purchases Worth US$1.50m - simplywall.st
Plus Therapeutics (NASDAQ:PSTV) vs. Aclaris Therapeutics (NASDAQ:ACRS) Head-To-Head Survey - Defense World
Aclaris Therapeutics Joins Russell 3000 and Russell 2000 Indexes - MSN
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Aclaris Therapeutics Inc (ACRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.32%
1.06%
자본화:
|
볼륨(24시간):